In Vitro Studies

In bacterial culture, ML 7 hydrochloride alone significantly increased fluorescence intensity compared with the control group, with ethidium bromide used as a fluorescent probe. In LSEC treated with ML 7 hydrochloride, most cells became defenestrated, while cells remaining partially fenestrated showed a greater proportion of fenestrations > 200 nm at 20 µM than in the control. In rat small intestines, ML 7 hydrochloride administered before PAF stimulation failed to prevent PAF-induced vasoconstriction in the ML-7 + PAF comparison with platelet-activating factor alone. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Fluorescence intensity in bacterial culture

Cell-based study · bacterial culture [1]

Ethidium bromide (EtBr) efflux assay: ML-7 (32-128 μg/mL), at 37°C for 1 h. The application of ML-7 alone caused significant increase of fluorescence intensity compared with the control group.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
fluorescence intensity	Reported result ML-7 (32-128 μg/mL), at 37°C for 1 h; ethidium bromide (EtBr) as a fluorescent probe: the application of ML-7 alone caused significant increase of fluorescence intensity compared with the control group.	[1]

Literature-Reported Treatment Conditions

Treatment concentration: 32-128 μg/mL
Exposure duration: at 37°C for 1 h
Method: co-incubated
Co-treatment: Other interventions in this design: EtBr 5 μM. Compound effect isolated by the comparison: ML-7 alone caused significant increase of fluorescence intensity compared with the control group.
Reported limits: Not stated in the sentences used: vehicle.

Methods and source locations

Compound reported in the paper: ML 7 hydrochloride; Compound label in the paper: ML 7

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Ethidium Bromide Efflux Assay (S59, S60); Results > Synergistic Mechanism of ML-7 in Combination With Tigecycline (S121, S122)

fluorescence intensity: fluorescence intensity; comparator: control group — Materials and Methods > Ethidium Bromide Efflux Assay (S60); Results > Synergistic Mechanism of ML-7 in Combination With Tigecycline (S121, S122)

Fenestration Changes in LSEC

Cell-based study · LSEC [2]

The porosity and distributions of fenestrations’ diameters were calculated for those cells that remained partially fenestrated; however, most of the cells became defenestrated. The proportion of fenestrations > 200 nm changed from 7% for the control up to 38% for 20 µM ML-7.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
proportion of fenestrations > 200 nm	proportion of fenestrations > 200 nm 38%	[2]

Literature-Reported Treatment Conditions

Treatment concentration: 20 µM
Exposure duration: 60 min of treatment; 10 µM of ML-7 for 60 min followed by removing the inhibitor by rinsing with a fresh medium and fixation after 2 further hours in culture.
Reported limits: Not stated in the sentences used: route, vehicle.

Methods and source locations

Compound reported in the paper: ML 7 hydrochloride; Compound label in the paper: ML 7

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.1. Modulation of MLC Phosphorylation > 2.1.2. MLCK Pathway (S59, S60, S63, S65, S68); Figure 4 legend (S204)

proportion of fenestrations > 200 nm: proportion of fenestrations > 200 nm; comparator: control — 2. Results > 2.1. Modulation of MLC Phosphorylation > 2.1.2. MLCK Pathway (S63, S65); Figure 4 legend (S204)

PAF-induced vasoconstriction in rat small intestines

Cell-based study · small intestines from non-fasted rats; female Wistar rats; n = 5 [3]

Small intestines from non-fasted female Wistar rats were perfused with ML 7 hydrochloride at 35 µM before PAF stimulation. ML-7 + PAF, compared with platelet-activating factor alone, failed to prevent PAF-induced vasoconstriction.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
PAF-induced vasoconstriction	Reported result ML-7 (35 µM), 20 minutes before stimulation with PAF: ML-7 failed to prevent the PAF-induced vasoconstriction.	[3]

Literature-Reported Treatment Conditions

Treatment concentration: 35 µM
Exposure duration: 20 minutes before stimulation with PAF
Method: perfused
Co-treatment: Other interventions in this design: PAF 0.5 nmol. Compound effect isolated by the comparison: ML-7 + PAF; platelet-activating factor alone.
Reported limits: Not stated in the sentences used: vehicle.

Methods and source locations

Compound reported in the paper: ML 7 hydrochloride; Compound label in the paper: ML 7

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Calcium and cAMP (S17); Results > Kinases (S62); Methods > Animals (S87); Methods > Study design (S95, S96, S98); Methods > Isolated perfusion and analysis (S100)

PAF-induced vasoconstriction: PAF-induced vasoconstriction; comparator: PAF, n = 5 — Results > Kinases (S62); Methods > Study design (S96, S98)

In Vivo Studies

Male Drosophila melanogaster of the wild-type Canton-S line received ML 7 hydrochloride at 1 μM on the medium surface for 10 days. Treatment increased late mortality. [4]

Late Mortality in Male Drosophila

Animal study · Drosophila melanogaster wild-type Canton-S line; males [4]

ML7 at concentration of 1 μM increased late mortality (p < 0.01) in males, but at concentrations of 0.1 μM and 1 μM reduced late mortality (p < 0.05) in females.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
late mortality	Reported result ML7 at concentration of 1 μM increased late mortality (p < 0.01) in males, but at concentrations of 0.1 μM and 1 μM reduced late mortality (p < 0.05) in females.	[4]

Conditions shared by the study groups

Route: pipetted onto the medium surface of each experimental vial
Treatment course: Treatment with inhibitors was started from the first day of imago life and continued for 10 days
Vehicle: 50% (v/v) solution of ethanol in water

Study groups and reported outcomes
Group / dose	Comparator	Observed result	Reference
ML 7 hydrochloride 1 μM	30 μL of corresponding solvent	ML7 at concentration of 1 μM increased late mortality (p < 0.01) in males, but at concentrations of 0.1 μM and 1 μM reduced late mortality (p < 0.05) in females.	[4]

ML 7 hydrochloride 1 μM: Model: Drosophila melanogaster wild-type Canton-S line; males

Methods and source locations

Compound reported in the paper: ML 7 hydrochloride; Compound label in the paper: ML 7

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.2. Effects on Survival (S36); 4. Materials and Methods > 4.1. Drosophila Strain and Experimental Conditions (S55); 4. Materials and Methods > 4.2. Treatment with Yap/Taz Inhibitors (S59, S61, S62, S63, S66); Figure 3 legend (S109)

late mortality: late mortality; comparator: 30 μL of corresponding solvent — 2. Results > 2.2. Effects on Survival (S36)

ML 7 hydrochloride 1 μM · 2. Results > 2.2. Effects on Survival (S36); 4. Materials and Methods > 4.2. Treatment with Yap/Taz Inhibitors (S62, S66)

Specifications

Manufacturer	Adooq Bioscience
Actions	Inhibitor
CAS Number	110448-33-4
Applications	MLCK inhibitor
Formula	C₁₅H₁₇IN₂O₂S.HCl
Molecular Weight	452.7
Synonyms	ML-7 HCl
SMILES	C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CC=C3I.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

Solvent	Reported Solubility
DMSO	77 mg/mL (170.07 mM)
Water	Insoluble
Ethanol	Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

[1] Sun L, Sun L, Li X, et al. A Novel Tigecycline Adjuvant ML-7 Reverses the Susceptibility of Tigecycline-Resistant Klebsiella pneumoniae. Front Cell Infect Microbiol (2021). PMID: 35071055 DOI: 10.3389/fcimb.2021.809542 Source material
[2] Zapotoczny B, Szafranska K, Lekka M, et al. Tuning of Liver Sieve: The Interplay between Actin and Myosin Regulatory Light Chain Regulates Fenestration Size and Number in Murine Liver Sinusoidal Endothelial Cells. Int J Mol Sci (2022). PMID: 36077249 DOI: 10.3390/ijms23179850 Source material
[3] Lautenschläger I, Wong YL, Sarau J, et al. Signalling mechanisms in PAF-induced intestinal failure. Sci Rep (2017). PMID: 29042668 DOI: 10.1038/s41598-017-13850-x Source material
[4] Golubev DA, Zemskaya NV, Gorbunova AA, et al. Studying the Geroprotective Properties of YAP/TAZ Signaling Inhibitors on Drosophila melanogaster Model. Int J Mol Sci (2023). PMID: 36983079 DOI: 10.3390/ijms24066006 Source material

Publications

1 publication citing this product

Praneeth Siripurapu, .et al. , J Biol Chem, 2017, Oct 20; 292(42): 17482-17495 PMID: 28864771

Documents & Downloads

ML 7 hydrochloride

Publications for ML 7 hydrochloride

Select a Size

Package Sizes

DMSO Solution